Spinal Muscular Atrophy 1 Clinical Trial
Official title:
Evaluation of Palliative and Supportive Care for Spinal Muscular Atrophy (SMA) Type 1 Patients
The purpose of this study is to evaluate the quality of supportive and palliative care for SMA type 1 patients.
Spinal Muscular Atrophy Type I (SMA I) is the most severe form of SMA. It presents in infancy and death occurs by 2 years. There is actually no curative treatment for this pathology. Support and help must be provided from the time of presentation till death and usually this period is quite short, about a couple of months. Variations in medical practice have be seen, depending on the medical experience and sometimes coupled with differences in family resources and values. The aim of the study is to evaluate the needs of the patients and their families, the medical practices, and to describe a cohort of SMA type 1 patients with the natural history of this disease. For this, a follow-up diary will be done, and this diary will be completed by the families and the different practitioners working with the patient. Will be noted in it : physical signs, all therapeutic choices and actions, evaluation of the pain and treatments. A special part of this follow-up diary will be completed by the medical doctors, after the death of the patient, with all the medication used at time of death and the conditions of the death. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist. This questionnaire will estimate the benefice of the follow-up diary, and the improvements to give in the diagnostic strategies, recommendations for assessment and monitoring, and therapeutic interventions in SMA type 1. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03421977 -
Long-Term Follow-up Study for Patients From AVXS-101-CL-101
|
||
| Completed |
NCT02122952 -
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
|
Phase 1 | |
| Recruiting |
NCT06191354 -
A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
|
N/A |